Citation Impact
Citing Papers
Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia
2006
A mechanosensory complex that mediates the endothelial cell response to fluid shear stress
2005 StandoutNature
Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases
2001
Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes
2010
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
2002
Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA
2005 StandoutNobel
The Vascular Endothelial Growth Factor Receptor Kdr/Flk–1 Is A Major Regulator of Malignant Ascites Formation in the Mouse Hepatocellular Carcinoma Model
2001
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
2001 Standout
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
2005 StandoutNobel
mTOR Signaling in Growth Control and Disease
2012 Standout
The hypoxic response of tumors is dependent on their microenvironment
2003
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling
2011
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
2005 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Endothelial cell migration directs testis cord formation
2008
Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
2005 Standout
Regulation of angiogenesis by the aging suppressor gene klotho
2002
Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial Cells
2009
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
2001
Imaging in the era of molecular oncology
2008 StandoutNature
Adhesion events in angiogenesis
2001
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 Standout
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors
2012
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Vascular Endothelial Growth Factor and Angiogenesis
2004 Standout
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
2005
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
The biology of VEGF and its receptors
2003 Standout
A New Weapon for Attacking Tumor Blood Vessels
2008 StandoutNobel
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
2000
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Iterative In Situ Click Chemistry Creates Antibody‐like Protein‐Capture Agents
2009 StandoutNobel
Lymphangiogenesis in development and human disease
2005 StandoutNature
Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways
2007
Angiogenesis in life, disease and medicine
2005 StandoutNature
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Invasion as limitation to anti-angiogenic glioma therapy
2003
‘Accidental’ anti-angiogenic drugs
2000
Malignant Gliomas in Adults
2008 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
2003
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
Cancer immunotherapy comes of age
2011 StandoutNature
Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
2003
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection
2011 StandoutNobel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
2000
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice
2002
Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF
2004
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice
2007 StandoutNobel
VEGF: an update on biological and therapeutic aspects
2000
Angiogenesis as a therapeutic target
2005 StandoutNature
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
2001
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
2002
A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity
2008
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
2010
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
2012
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
2001
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
1997 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
2000
VEGF and its receptors
2004
VEGF-Trap: A VEGF blocker with potent antitumor effects
2002
Mouse 4T1 Breast Tumor Model
2000
Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
2001
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
2003
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
2001
VE-Cadherin Regulates Endothelial Actin Activating Rac and Increasing Membrane Association of Tiam
2002
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
2001
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis
2004
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
2002
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
2007
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
2009
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors
2007
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
2000
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
2002
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
2001
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
2004
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of William O’Connor being referenced
Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.
2000
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
1999